Summary

Eligibility
for people ages 12 years and up (full criteria)
Location
at Sacramento, California and other locations
Dates
study started
completion

Description

Summary

The purpose of this study evaluates the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who were heterozygous for F508del and a minimal function mutation (F/MF participants).

Official Title

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (CF) Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Keywords

Cystic Fibrosis, Fibrosis, Ivacaftor, Elexacaftor, VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA

Eligibility

You can join if…

Open to people ages 12 years and up

  • Heterozygous for F508del and a minimal function mutation (F/MF genotype)
  • Forced expiratory volume in 1 second (FEV1) value >=40% and <=90% of predicted mean for age, sex, and height for participants currently receiving ELX/TEZ/IVA therapy; FEV1 >=40% and <=80% for participants not currently receiving ELX/TEZ/IVA

You CAN'T join if...

  • History of solid organ or hematological transplantation
  • Hepatic cirrhosis with portal hypertension, moderate hepatic impairment (Child Pugh Score 7 to 9), or severe hepatic impairment (Child Pugh Score 10 to 15)
  • Lung infection with organisms associated with a more rapid decline in pulmonary status
  • Pregnant or breast-feeding females

    Other protocol defined Inclusion/Exclusion criteria may apply

Locations

  • University of California Davis Medical Center
    Sacramento California 95817 United States
  • Kaiser Permanente
    Oakland California 94611 United States

Details

Status
accepting new patients
Start Date
Completion Date
Sponsor
Vertex Pharmaceuticals Incorporated
Links
Sign up for this study
ID
NCT05033080
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 435 people participating
Last Updated